Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Product Name : Keveyis-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2023
Lead Product(s) : Dichlorphenamide
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
